The American Journal of Medicine
Volume 121, Issue 1 , Pages 58-65, January 2008

CARMELA: Assessment of Cardiovascular Risk in Seven Latin American Cities

  • Herman Schargrodsky, MD

      Affiliations

    • Department of Cardiology, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
    • Corresponding Author InformationRequests for reprints should be addressed to Herman Schargrodsky, MD, Ramón Falcón 2239, 4o. piso, Ciudad Autónoma de Buenos Aires, Argentina, 1406.
  • ,
  • Rafael Hernández-Hernández, MD

      Affiliations

    • Clinical Pharmacology Unit and Hypertension Clinic, School of Medicine, Universidad Centroccidental “Lisandro Alvarado,” Decanato de Medicina, Barquisimeto, Venezuela
  • ,
  • Beatriz Marcet Champagne, PhD

      Affiliations

    • InterAmerican Heart Foundation, Dallas, Tex
  • ,
  • Honorio Silva, MD

      Affiliations

    • Science and Medical Professional Development, Pfizer, Inc., New York, NY
  • ,
  • Raúl Vinueza, MD

      Affiliations

    • Latin America Biometrics Center, Pfizer, Inc., New York, NY
  • ,
  • Luis Carlos Silva Ayçaguer, PhD

      Affiliations

    • Centro Nacional de Información de Ciencias Médicas, La Habana, Cuba
  • ,
  • Pierre-Jean Touboul, MD

      Affiliations

    • Bichet Hospital and University, Paris, France
  • ,
  • Carlos Pablo Boissonnet, MD

      Affiliations

    • Coronary Care Unit, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno,” Ciudad Autónoma de Buenos Aires, Argentina
  • ,
  • Jorge Escobedo, MD

      Affiliations

    • Medical Research Unit on Clinical Epidemiology, Mexican Social Security Institute, Mexico City, Mexico
  • ,
  • Fabio Pellegrini, MSc

      Affiliations

    • Consorzio Mario Negri Sud, Chieti, Italy
  • ,
  • Alejandro Macchia, MD

      Affiliations

    • Consorzio Mario Negri Sud, Chieti, Italy
  • ,
  • Elinor Wilson, PhD

      Affiliations

    • Assisted Human Reproduction Canada, Ottawa, Ontario, Canada.
  • ,
  • CARMELA Study Investigators

Abstract 

Objective

This cross-sectional, population-based observational study using stratified multistage sampling assessed the prevalence of cardiovascular risk factors and carotid plaques and measured carotid intima-media thickness in individuals living in major cities in 7 Latin American countries.

Patients and Methods

The study comprised individuals (n=11,550) aged 25 to 64 years, living in Barquisimeto, Bogota, Buenos Aires, Lima, Mexico City, Quito, and Santiago. Data on anthropometric parameters, blood pressure, fasting glucose, total and high-density lipoprotein cholesterol, triglycerides, carotid intima-media thickness, carotid plaque, and smoking status were collected through household interviews and clinical, biochemical, and sonographic measurements.

Results

The overall prevalence rates (ranges across cities) were as follows: hypertension (≥140/90 mm Hg or pharmacologic treatment), 18% (9%-29%); hypercholesterolemia (total cholesterol ≥240 mg/dL), 14% (6%-20%); diabetes (glycemia≥126 mg/dL or self-reported diabetes), 7% (4%-9%); metabolic syndrome, 20% (14%-27%); obesity (body mass index ≥30 kg/m2), 23% (18%-27%); smoking, 30% (22%-45%); and plaque, 8% (5%-14%). The mean intima-media thickness was 0.65 mm (0.60-0.74 mm).

Conclusion

The prevalence of hypertension mirrored the world average in 3 cities but was lower in the rest. Hypercholesterolemia was highly prevalent even in countries of different socioeconomic levels. The prevalence of diabetes was similar to that in the developed countries. Tobacco use in women living in Santiago and Buenos Aires was among the world’s highest. Intima-media thickness and carotid plaque prevalences varied widely.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The CARMELA Study was funded through an unrestricted research grant from Pfizer, Inc.

PII: S0002-9343(07)00940-0

doi:10.1016/j.amjmed.2007.08.038

The American Journal of Medicine
Volume 121, Issue 1 , Pages 58-65, January 2008